Fredrick B. Hagemeister

Statistics

Publications

178

Citations

12.6K

H-Index

Active since

1981

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Lymphoma Research Foundation

Baylor College of Medicine

Fredrick B. Hagemeister is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and hematologic oncology.

Publications per year

1981–2023

178

Publications

178

Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia

Deborah A. Thomas, Stefan Faderl, Susan O’Brien et al. · Cancer · 2006 · 564 citations

Medicine, Immunology, Oncology +14

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

Jason R. Westin, Fuliang Chu, Min Zhang et al. · The Lancet Oncology · 2013 · 530 citations

Pharmacy, Immunology, Pharmacotherapy +13

ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.

William S. Velasquez, Peter McLaughlin, Fredrick B. Hagemeister et al. · Journal of Clinical Oncology · 1994 · 430 citations

Medicine, Oncology, Pharmacotherapy +13

Double hit lymphoma: the <scp>MD A</scp> nderson <scp>C</scp> ancer <scp>C</scp> enter clinical experience

Yasuhiro Oki, Mansoor Noorani, Pei Lin et al. · British Journal of Haematology · 2014 · 364 citations

Medicine, Hematology, Oncology +13

Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality

Issa F. Khouri, Rima M. Saliba, Sergio Giralt et al. · Blood · 2001 · 363 citations

Life Sciences, Hematology, Immunology +14

1–5 of 178